<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="81702"><DrugName>cymipristone</DrugName><DrugSynonyms><Name><Value>cymipristone</Value></Name><Name><Value>samistone</Value></Name><Name><Value>ZXH-951</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1014969">Tongji Medical College</CompanyOriginator><CompaniesSecondary><Company id="1010428">Zhejiang Xianju Pharmaceutical Corp Ltd</Company><Company id="1014969">Tongji Medical College</Company><Company id="1082085">Shanghai Three-Alliance Biotechnologies Co Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1010428" type="Company"><TargetEntity id="4297898688" type="organizationId">Zhejiang Xianju Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1014969" type="Company"><TargetEntity id="5035524727" type="organizationId">Tongji Medical College of Hust</TargetEntity></SourceEntity><SourceEntity id="1082085" type="Company"><TargetEntity id="5036179665" type="organizationId">Shanghai Sanhe Biotechnology Co Ltd</TargetEntity></SourceEntity><SourceEntity id="158" type="ciIndication"><TargetEntity id="B20" type="ICD10"/><TargetEntity id="042" type="ICD9"/><TargetEntity id="10020161" type="MEDDRA"/><TargetEntity id="D015658" type="MeSH"/><TargetEntity id="-841965209" type="omicsDisease"/><TargetEntity id="862" type="siCondition"/></SourceEntity><SourceEntity id="1778" type="ciIndication"><TargetEntity id="541" type="siCondition"/></SourceEntity><SourceEntity id="93" type="ciIndication"><TargetEntity id="10012378" type="MEDDRA"/><TargetEntity id="D003863" type="MeSH"/><TargetEntity id="-508468160" type="omicsDisease"/><TargetEntity id="53" type="siCondition"/></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity></SourceEntity><SourceEntity id="532" type="Action"><TargetEntity id="561" type="Mechanism">Progesterone Receptor Antagonists</TargetEntity></SourceEntity><SourceEntity id="1886" type="Action"><TargetEntity id="1739" type="Mechanism">Glucocorticoid Receptor (GR) Antagonists</TargetEntity><TargetEntity id="804" type="Mechanism">Antiglucocorticoids</TargetEntity></SourceEntity><SourceEntity id="PTGT-01604" type="ciTarget"><TargetEntity id="14903792952413" type="siTarget">Progesterone receptor</TargetEntity><TargetEntity id="1100" type="omicsTarget"/><TargetEntity id="-1973148911" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="W">Withdrawn</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="18">National Science and Technology Major Project</RegulatoryDesignation><RegulatoryDesignation id="19">Special Review Project</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="158">HIV infection</Indication><Indication id="1778">Female contraception</Indication><Indication id="93">Depression</Indication></IndicationsSecondary><ActionsPrimary><Action id="532">Progesterone receptor antagonist</Action><Action id="1886">Glucocorticoid receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="2941">Antidepressant</Action><Action id="7250">Contraceptive</Action><Action id="991">Antiviral</Action></ActionsSecondary><Technologies><Technology id="90">Steroid</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology><Technology id="585">Oral formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>N6A</Code><Name>ANTI-DEPRESSANTS AND MOOD STABILISERS</Name></Ephmra><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra></EphmraCodes><LastModificationDate>2018-12-03T09:27:52.000Z</LastModificationDate><ChangeDateLast>2017-10-18T00:00:00.000Z</ChangeDateLast><AddedDate>2012-12-06T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1010428" linkType="Company"&gt;Zhejiang Xianju Pharmaceutical&lt;/ulink&gt;, through &lt;ulink linkID="1082085" linkType="Company"&gt;Shanghai Three-Alliance Biotechnologies&lt;/ulink&gt; (a joint venture  with &lt;ulink linkID="28974" linkType="Company"&gt;Shanghai Zhongxi Pharmaceutical&lt;/ulink&gt; and &lt;ulink linkID="1082087" linkType="Company"&gt;Shanghai Siwei Pharmaceutical and Chemical&lt;/ulink&gt;), under license from &lt;ulink linkID="1014969" linkType="Company"&gt;Tongji Medical College&lt;/ulink&gt;, is developing an oral tablet formulation of  cymipristone (ZXH-951, samistone), a progestogen antagonist as a contraceptive for early pregnancy [&lt;ulink linkID="1407670" linkType="Reference"&gt;1407670&lt;/ulink&gt;], [&lt;ulink linkID="1336318" linkType="Reference"&gt;1336318&lt;/ulink&gt;], [&lt;ulink linkID="1336319" linkType="Reference"&gt;1336319&lt;/ulink&gt;], [&lt;ulink linkID="1407678" linkType="Reference"&gt;1407678&lt;/ulink&gt;]. In  April 2013, an NDA was filed in China [&lt;ulink linkID="1407670" linkType="Reference"&gt;1407670&lt;/ulink&gt;], [&lt;ulink linkID="1406447" linkType="Reference"&gt;1406447&lt;/ulink&gt;]. In December 2015, the application was withdrawn [&lt;ulink linkID="1727692" linkType="Reference"&gt;1727692&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Zhejiang Xianju Pharmaceutical, through   Shanghai Three-Alliance Biotechnologies, was  also investigating cymipristone and its analogs, for the potential treatment of depression and HIV infection [&lt;ulink linkID="1336318" linkType="Reference"&gt;1336318&lt;/ulink&gt;]. In September 2009, development was ongoing  [&lt;ulink linkID="1336318" linkType="Reference"&gt;1336318&lt;/ulink&gt;]. However, no further development has been reported since that time.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In April 2013, an NDA was filed in China [&lt;ulink linkID="1406447" linkType="Reference"&gt;1406447&lt;/ulink&gt;]; at that time, the application was granted  "Special Review Project" and  "National Science and Technology Major Project" [&lt;ulink linkID="1971669" linkType="Reference"&gt;1971669&lt;/ulink&gt;].In December 2015, the application was withdrawn [&lt;ulink linkID="1727692" linkType="Reference"&gt;1727692&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2003, the company intended to develop the product as a class 1.1 chemical drug in China [&lt;ulink linkID="1727694" linkType="Reference"&gt;1727694&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;By September 2009, a phase III trial had been initiated [&lt;ulink linkID="1407678" linkType="Reference"&gt;1407678&lt;/ulink&gt;], [&lt;ulink linkID="1336318" linkType="Reference"&gt;1336318&lt;/ulink&gt;]; by April 2013, a phase III trial had been completed [&lt;ulink linkID="1407670" linkType="Reference"&gt;1407670&lt;/ulink&gt;], [&lt;ulink linkID="1406447" linkType="Reference"&gt;1406447&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By September 2009, a phase II trial had been completed. Data showed that cymipristone could terminate early pregnancy, with shortened bleeding time  [&lt;ulink linkID="1407678" linkType="Reference"&gt;1407678&lt;/ulink&gt;], [&lt;ulink linkID="1336318" linkType="Reference"&gt;1336318&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2007, the application for phase III trials was approved by CFDA [&lt;ulink linkID="1727692" linkType="Reference"&gt;1727692&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By February 2004, a phase I trial was planned [&lt;ulink linkID="1407678" linkType="Reference"&gt;1407678&lt;/ulink&gt;], [&lt;ulink linkID="1336318" linkType="Reference"&gt;1336318&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2003, an IND was filed in China [&lt;ulink linkID="1727694" linkType="Reference"&gt;1727694&lt;/ulink&gt;]; in March 2004, the application was approved [&lt;ulink linkID="1727692" linkType="Reference"&gt;1727692&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In August 2012, preclinical data was published showing that cymipristone terminated early pregnancy of rhesus monkeys by oral administration, with shortened bleeding time and amount [&lt;ulink linkID="1407902" linkType="Reference"&gt;1407902&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;By September 2009, the project had received funding as part of 863 Plan of Chinese government's 10th-5 year plan [&lt;ulink linkID="1407940" linkType="Reference"&gt;1407940&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2002, Shanghai Three-Alliance Biotechnologies, a joint venture of Shanghai Zhongxi Pharmaceutical, Zhejiang Xianju Pharmaceutical and Shanghai Siwei Pharmaceutical and Chemical with rights of  37.5%, 37.5% and   25% respectively,  was set up to promote the development of cymipristone and its analogs [&lt;ulink linkID="1407940" linkType="Reference"&gt;1407940&lt;/ulink&gt;], [&lt;ulink linkID="1336318" linkType="Reference"&gt;1336318&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1010428">Zhejiang Xianju Pharmaceutical Corp Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1778">Female contraception</Indication><StatusDate>2015-12-14T00:00:00.000Z</StatusDate><Source id="1727692" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1082085">Shanghai Three-Alliance Biotechnologies Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1778">Female contraception</Indication><StatusDate>2015-12-14T00:00:00.000Z</StatusDate><Source id="1727692" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1010428">Zhejiang Xianju Pharmaceutical Corp Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2011-03-02T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1010428">Zhejiang Xianju Pharmaceutical Corp Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate>2011-03-02T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1082085">Shanghai Three-Alliance Biotechnologies Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate>2011-03-02T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1082085">Shanghai Three-Alliance Biotechnologies Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2011-03-02T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014969">Tongji Medical College</Company><Country id="CN">China</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1778">Female contraception</Indication><StatusDate>2002-08-31T00:00:00.000Z</StatusDate><Source id="1407940" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1014969">Tongji Medical College</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1778">Female contraception</Indication><StatusDate>2002-08-31T00:00:00.000Z</StatusDate><Source id="1407940" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1082085">Shanghai Three-Alliance Biotechnologies Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1778">Female contraception</Indication><StatusDate>2002-04-30T00:00:00.000Z</StatusDate><Source id="1727692" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1010428">Zhejiang Xianju Pharmaceutical Corp Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1778">Female contraception</Indication><StatusDate>2002-04-30T00:00:00.000Z</StatusDate><Source id="1727692" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1082085">Shanghai Three-Alliance Biotechnologies Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1778">Female contraception</Indication><StatusDate>2009-09-12T00:00:00.000Z</StatusDate><Source id="1336318" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1010428">Zhejiang Xianju Pharmaceutical Corp Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1778">Female contraception</Indication><StatusDate>2009-09-12T00:00:00.000Z</StatusDate><Source id="1336318" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1082085">Shanghai Three-Alliance Biotechnologies Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1778">Female contraception</Indication><StatusDate>2009-09-12T00:00:00.000Z</StatusDate><Source id="1336318" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1010428">Zhejiang Xianju Pharmaceutical Corp Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1778">Female contraception</Indication><StatusDate>2009-09-12T00:00:00.000Z</StatusDate><Source id="1336318" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1082085">Shanghai Three-Alliance Biotechnologies Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2009-09-12T00:00:00.000Z</StatusDate><Source id="1336318" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1010428">Zhejiang Xianju Pharmaceutical Corp Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2009-09-12T00:00:00.000Z</StatusDate><Source id="1336318" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1010428">Zhejiang Xianju Pharmaceutical Corp Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate>2009-09-12T00:00:00.000Z</StatusDate><Source id="1336318" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1082085">Shanghai Three-Alliance Biotechnologies Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate>2009-09-12T00:00:00.000Z</StatusDate><Source id="1336318" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1010428">Zhejiang Xianju Pharmaceutical Corp Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1778">Female contraception</Indication><StatusDate>2013-04-02T00:00:00.000Z</StatusDate><Source id="1406447" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1082085">Shanghai Three-Alliance Biotechnologies Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1778">Female contraception</Indication><StatusDate>2013-04-02T00:00:00.000Z</StatusDate><Source id="1406447" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="18">National Science and Technology Major Project</RegulatoryDesignation><OwnerCompany id="1082085">Shanghai Three-Alliance Biotechnologies Co Ltd</OwnerCompany><Country id="CN">China</Country><Indication id="1778">Female contraception</Indication><AwardedIndication>Female contraception</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2013-04-07T00:00:00.000Z</MileStoneDate><Source id="1971669" type="OTHER"/></Row><Row><RegulatoryDesignation id="18">National Science and Technology Major Project</RegulatoryDesignation><OwnerCompany id="1010428">Zhejiang Xianju Pharmaceutical Corp Ltd</OwnerCompany><Country id="CN">China</Country><Indication id="1778">Female contraception</Indication><AwardedIndication>Female contraception</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2013-04-07T00:00:00.000Z</MileStoneDate><Source id="1971669" type="OTHER"/></Row><Row><RegulatoryDesignation id="19">Special Review Project</RegulatoryDesignation><OwnerCompany id="1082085">Shanghai Three-Alliance Biotechnologies Co Ltd</OwnerCompany><Country id="CN">China</Country><Indication id="1778">Female contraception</Indication><AwardedIndication>Female contraception</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2013-04-07T00:00:00.000Z</MileStoneDate><Source id="1971669" type="OTHER"/></Row><Row><RegulatoryDesignation id="19">Special Review Project</RegulatoryDesignation><OwnerCompany id="1010428">Zhejiang Xianju Pharmaceutical Corp Ltd</OwnerCompany><Country id="CN">China</Country><Indication id="1778">Female contraception</Indication><AwardedIndication>Female contraception</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2013-04-07T00:00:00.000Z</MileStoneDate><Source id="1971669" type="OTHER"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00822"><Name>Glucocorticoid receptor</Name><SwissprotNumbers><Swissprot>O13186</Swissprot><Swissprot>O46567</Swissprot><Swissprot>O73673</Swissprot><Swissprot>P04150</Swissprot><Swissprot>P06536</Swissprot><Swissprot>P06537</Swissprot><Swissprot>P35547</Swissprot><Swissprot>P49115</Swissprot><Swissprot>P49843</Swissprot><Swissprot>P49844</Swissprot><Swissprot>P59667</Swissprot><Swissprot>P79269</Swissprot><Swissprot>P79686</Swissprot><Swissprot>Q5R9P5</Swissprot><Swissprot>Q95267</Swissprot><Swissprot>Q9N1U3</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01604"><Name>Progesterone receptor</Name><SwissprotNumbers><Swissprot>P06186</Swissprot><Swissprot>P06401</Swissprot><Swissprot>P07812</Swissprot><Swissprot>P79373</Swissprot><Swissprot>Q00175</Swissprot><Swissprot>Q28590</Swissprot><Swissprot>Q63449</Swissprot><Swissprot>Q8AYI2</Swissprot><Swissprot>Q9GLW0</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1082085">Shanghai Three-Alliance Biotechnologies Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="CM27909">Huazhong University of Science and Technology</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)c5ccc(cc5)N(C)C6CCCCC6)C)O</Smiles></StructureSmiles><Deals><Deal id="146108" title="Shanghai Three-Alliance Biotechnologies to develop Tongji Medical College's formulation of cymipristone"/></Deals><PatentFamilies><PatentFamily id="2032522" number="WO-2007009397" title="Use of cymipristones for treating aids"/><PatentFamily id="255036" number="WO-2006063526" title="Use of cymipristone for treating depression"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Three-Alliance Biotechnologies Co Ltd" id="1082085"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>